Bicara Therapeutics INC Form 4 insider transactions

Bicara Therapeutics Inc.'s Chief Legal Officer, Lara Meisner, exercised stock options and subsequently sold 15,829 shares of common stock for a weighted average price of $10.43 per share, as part of a pre-arranged 10b5-1 trading plan.

Bicara Therapeutics Inc. Director Kate Haviland was granted 23,746 stock options with an exercise price of $11.48 per share, vesting upon the earlier of June 9, 2026, or the next Annual Meeting of Stockholders.

A recent SEC Form 4 filing reveals that Jake Simson, a director of Bicara Therapeutics Inc. and partner at RA Capital Management, L.P., was granted 23,746 stock options with an exercise price of $11.48.

Kiran Mazumdar-Shaw, a Director and 10% Owner of Bicara Therapeutics Inc., was granted 23,746 stock options with an exercise price of $11.48, vesting upon continued service.

Bicara Therapeutics Inc. Director Michael Powell was granted 23,746 stock options with an exercise price of $11.48, vesting based on continued service.

Bicara Therapeutics Inc. Director Nils Lonberg was granted 23,746 stock options with an exercise price of $11.48, vesting upon the earlier of June 9, 2026, or the next Annual Meeting of Stockholders.

Scott M. Robertson, a Director at Bicara Therapeutics Inc. (BCAX), was granted 23,746 stock options with an exercise price of $11.48 per share, vesting over time.

Bicara Therapeutics Inc. director Jake Simson was granted 23,746 stock options with an exercise price of $11.48, vesting upon the earlier of June 9, 2026, or the next Annual Meeting, though he disclaims beneficial ownership due to an arrangement with RA Capital Management.

Bicara Therapeutics Inc. Director Christopher Bowden was granted 23,746 stock options with an exercise price of $11.48, aligning his interests with shareholder value.

Lara Meisner, Chief Legal Officer of Bicara Therapeutics, executed stock sales and option exercises on March 14, 2025, according to a Form 4 filing.

RA Capital Management and related entities report changes in beneficial ownership of Bicara Therapeutics (BCAX) common stock following the company's initial public offering, including conversion of preferred stock and open market purchases.

TPG GP A, LLC, along with David Bonderman, James G. Coulter, and Jon Winkelried, reported changes in their beneficial ownership of Bicara Therapeutics Inc. common stock following the company's initial public offering.

FIL Ltd reports the conversion of Series Seed, B, and C Preferred Shares to Common Stock in Bicara Therapeutics (BCAX) following the completion of the company's initial public offering.

FMR LLC reports changes in beneficial ownership of Bicara Therapeutics common stock following the conversion of preferred shares in connection with the company's initial public offering.

James E. Flynn and related Deerfield entities report changes in beneficial ownership of Bicara Therapeutics Inc. common stock following the company's initial public offering.

RA Capital Management and related entities report acquiring stock options in Bicara Therapeutics, indicating potential future ownership.

Director Nils Lonberg acquired 23,746 stock options in Bicara Therapeutics on September 12, 2024.

Director Jake Simson of Bicara Therapeutics acquired stock options exercisable for 23,746 shares of common stock on September 12, 2024.

Biocon Ltd and Biocon Pharma Inc. report changes in their beneficial ownership of Bicara Therapeutics Inc. common stock following the conversion of preferred stock in connection with the company's initial public offering.

Director Kate Haviland acquired stock options in Bicara Therapeutics Inc. on September 12, 2024.

Director Scott M. Robertson acquires stock options in Bicara Therapeutics.

Kiran Mazumdar-Shaw, a director and 10% owner of Bicara Therapeutics Inc., reports changes in beneficial ownership due to the conversion of preferred stock to common stock following the company's initial public offering.